K B Phua,
F S Lim, Y L Lau,
E A S Nelson,
L M Huang,
S H Quak,
B W Lee,
Y L Teoh,
H Tang,
I Boudville,
L C Oostvogels,
P V Suryakiran,
I V Smolenov,
H H Han,
H L Bock
[show abstract]
[hide abstract]
ABSTRACT: This study evaluates the safety and efficacy against severe rotavirus gastroenteritis of the oral live attenuated human rotavirus vaccine RIX4414 (Rotarix) during the first 2 years of life in Asian infants from high-income countries. Healthy infants were enrolled to receive 2 doses of RIX4414 (N=5,359) or placebo (N=5,349). From 2 weeks post-dose 2 to 2 years of age, vaccine efficacy was 96.1% (95%CI:85.1%; 99.5%) against severe rotavirus gastroenteritis, 100% (95%CI:80.8%; 100%) against wild-type G1P[8] and 93.6% (95%CI:74.7%; 99.3%) against circulating non-G1 rotavirus types. No intussusception cases were reported within 31 days post-vaccination. RIX4414 shows a good safety profile and offers high protection during the first 2 years of life with potentially significant public health impact in this population.
Vaccine 09/2009; 27(43):5936-41. · 3.77 Impact Factor